Abstract of the disclosure

A gene encoding a tumor antigen that is capable of being recognized by and/or inducing cytotoxic T lymphocyte (CTL) in an HLA-A2 restricted manner was identified from cDNA library of human colon cancer cell line by using a gene expression cloning method, and further found was a peptide having an epitope of the tumor antigen, which is capable of being recognized by and/or inducing cytotoxic T lymphocyte (CTL) in an HLA-A2 restricted manner. In addition, a gene encoding a tumor antigen that is capable of being recognized by and/or inducing cytotoxic T lymphocyte (CTL) in an HLA-A26 restricted manner was identified from a cDNA library of human esophageal cancer cell line, and further found was a peptide having an epitope of the tumor antigen.

Further provided are a polypeptide and a peptide encoded by the above-described gene, a polynucleotide encoding any one of those or the complementary strand thereof, a recombinant vector, a transformant, an antibody against the polypeptide or the peptide, a compound that interacts with the polypeptide or the peptide and /or HLA-A2 or HLA-A26, a compound that interacts with the polynucleotide, a CTL inducer consisting of the peptide and/or polypeptide, a pharmaceutical composition comprising any one of those, a method for inducing CTL that comprises using the peptide and/or polypeptide, a method for producing the peptide and/or polypeptide, a method for screening for the compound, a method for measuring the same, and a reagent kit for use in the screening method or the measuring method.